EuropaBio calls for ambitious role of biotech following EC Competitiveness Compass

PRESS RELEASE
Brussels, 30 January 2025
EuropaBio welcomes the publication of the European Commission’s ‘’A Competitiveness Compass for the EU’’. The recognition of biotech as strategic technologies for a new EU competitiveness model based on innovation-led productivity is an important signal for industrial confidence into Europe.
Closing the innovation gap, accelerating decarbonisation, and increasing resilience will require simpler legislative frameworks that enable faster time to market and foster trust and public acceptance. Fully exploiting benefits of scale of the Single Market, boosting availability of finance, promoting skills and quality jobs, and ensuring coherence across policies at EU and national level will be key to reap the full benefits of the biotech revolution.
EuropaBio looks towards the EU Biotech Act to translate ambitions into legislations for all industrial sectors where biotechnologies and biomanufacturing can be applied and secure EU global leadership in biotech and life sciences.
Dr. Claire Skentelbery, Director General of EuropaBio, says “Biotechnology remains highly visible within policy direction for Europe and rightly so. The Competitiveness Compass is an important part of Europe’s strategic development and, for biotech, part of our future resilience and competitiveness.”
EuropaBio remains committed to engaging with stakeholders to support EU global competitiveness opportunities, making our industries stronger, greener and even more innovative through biotech.